AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01901848 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smokefreeVET
Description: SmokefreeVET is a program that was developed by the National Institutes of Health and Department of Veterans Affairs. The program includes a text messaging protocol for reaching out to Veterans who wish to stop smoking.
Study NCT02640300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Switching to clozapine with immediate or gradual antipsychotic discontinuation
Study NCT01008826 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: broccoli sprouts extract
Description: Glucoraphanin-rich broccoli sprouts extract: 800 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice Sulforaphane-rich broccoli sprouts extract: 150 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice
Study NCT03611530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coqun® ophthalmic solution
Description: Prostaglandin analogue (PGA) monotherapy + Coqun® ophthalmic solution
Study NCT03611530 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ophthalmic solution
Description: Prostaglandin analogue (PGA) monotherapy + Placebo ophthalmic solution
Study NCT02200341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT
Study NCT02200341 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PRT-PsyEd
Study NCT04561037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Field therapy (PEMFT)
Description: PEMFT was connected to electrical mains supplying 220v. Pair of applicators sized 16x10x3 cm was adjust to be over TMJ, on both sides of the face; the appliance was adjusted to the frequency of 50 HZ and intensity of 90 Gauss. Twelve PEMF treatment sessions of 30 min duration were provided 3 times per week TMJ mobilization techniques and isometric exercises against resistance for muscles of mastication
Study NCT04561037 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TMJ physical therapy program
Description: TMJ manual physical therapy program (mobilization and gentle isometric exercises) for 30, 3 times a week, for 4 weeks.
Study NCT01778712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-level intervention
Description: The development of a lifestyle program intended to intervene on the individual, social network and community over two years
Study NCT02711826 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polyclonal Regulatory T Cells
Description: Participants randomized to polyTregs group will receive a single infusion of 550 ± 450 x 10\^6 polyTregs.
Study NCT02711826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT02711826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Study NCT02711826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study NCT02711826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: All enrolled participants will be on MMF (or MPA below) at the time of study entry at a minimum dose of 1000mg per day.
Study NCT02711826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: All enrolled participants will be on MMF (or MPA below) at the time of study entry at a minimum dose of 1000mg per day.
Study NCT02711826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic acid
Description: All enrolled participants will be on MPA (or MMF above) at the time of study entry at a minimum dose of 720mg per day.
Study NCT02711826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid
Description: All enrolled participants will be on MPA (or MMF above) at the time of study entry at a minimum dose of 720mg per day.
Study NCT02711826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 650 mg acetaminophen, administered 30-60 minutes prior to infusion as pre-medication.
Study NCT02711826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 25-50 mg diphenhydramine intravenously or by mouth, administered 30-60 minutes prior to infusion as pre-medication.
Study NCT02711826 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy, Kidney
Study NCT02711826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy, Kidney
Study NCT02711826 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Draw
Study NCT02711826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draw
Study NCT02711826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Study NCT02711826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IS regimen conversion
Description: Conversion from Tacrolimus, a calcineurin inhibitors (CNI), to Everolimus, an mTOR inhibitor.
Study NCT01177852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine + dropropizine + pseudoephedrine
Description: Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).~Posology: The medicine treat will be as follows:~- Notuss® syrup Age: 2-5 years / Dosage: 5,0 mL Age: 6-12 years / Dosage: 10,0 ml
Study NCT00744744 — intervention group
Intervention type: OTHER
Intervention: informational intervention
Description: Patient educational information
Study NCT00744744 — intervention group
Intervention type: OTHER
Intervention: questionnaire administration
Description: Survey
Study NCT01177852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir).
Description: Dropropizine:~Age: 2 - 3 years / Dosage: 5,0 ml Age: 4 - 12 years / Dosage: 10,0 ml~Pseudoephedrine hydrochloride + brompheniramine maleate:~Age: 2 - 3 years / Dosage: 2,5 ml Age: 4 - 6 years / Dosage: 5,0 ml Age: 7 - 9 years / Dosage: 7,5 ml Age: 10 - 12 years / Dosage: 10,0 ml
Study NCT00145041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposomes Injection
Description: Marqibo (VSLI) 1.0 mg/m2 delivered by intravenous infusion over 1 hour every 2 weeks.
Study NCT01550978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AnapnoGuard 100 System
Description: AnapnoGuard™ 100 Respiratory Guard System is intended for airway management by oral/nasal intubation while providing continuous endotracheal cuff pressure control using non-invasive measurement and monitoring of carbon dioxide concentration in the subglottic space and evacuation of secretions from above the endotracheal tube's cuff.
Study NCT00839540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: micafungin
Description: 100 mg qd by slow IV infusion for 24 h
Study NCT00839540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micafungin
Description: 200 mg qd by slow IV infusion for 24 h
Study NCT00839540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caspofungin
Description: 70 mg LD followed by 50 mg qd by slow IV infusion for 24 h
Study NCT04324242 — intervention group
Intervention type: OTHER
Intervention: abdominal hallowing maneuver
Description: abdominal hallowing maneuver includes tucking navel in and up. To be able to control the effect of breathing it was instructed to start the maneuver at the end of the expiration. During the maneuver it was instructed to focus on increasing the thickness of TrA without increasing the thickness of IO and EO
Study NCT02984319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cherry versus placebo concentrate
Description: Acute cherry concentrate
Study NCT00744744 — intervention group
Intervention type: PROCEDURE
Intervention: management of therapy complications
Description: Survey
Study NCT00744744 — intervention group
Intervention type: PROCEDURE
Intervention: psychosocial assessment and care
Description: Survey
Study NCT00430313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electro-Stimulation of Yongquan (K1) Acupoint
Description: Electro-stimulation at a inactive site on the bottom of the foot (a placebo site).
Study NCT02235116 — intervention group
Intervention type: OTHER
Intervention: Survey
Study NCT01726920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naratriptan + naproxen
Description: Tablets containing naratriptan 2,5 mg + naproxen 500 mg
Study NCT04131101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Organizing
Description: The intervention will be community organizing and will consist of engaging tenants, health providers, legal service staff, social service agencies and advocacy organizations (e.g. ACORN). Each building team will identify initial priorities and then invite all building members to discuss and to finalize, as well as a plan for change. Building teams will engage in advocacy to TCHC and its representatives, and other city departments as appropriate. Engaging in advocacy will consist of a wide range of activities but essentially means presenting evidence (e.g. personal experiences, data) to policymakers and decision makers to affect change.
Study NCT03793920 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Facial Emotion Test
Description: All tasks will be delivered using a laptop and E-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh), which will also be used to collect behavioral responses.
Study NCT02984319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cherry versus placebo concentrate
Description: Acute cherry concentrate
Study NCT03793920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Emotion Test
Description: All tasks will be delivered using a laptop and E-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh), which will also be used to collect behavioral responses.
Study NCT03891329 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Acticor/Rivacor ICDs/CRT-Ds
Description: pre-defined device programming, measurements and follow-up schedule
Study NCT03891329 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Plexa S DX
Description: Implantation, measurements and follow-up schedule
Study NCT00992563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-39324 ophthalmic suspension
Study NCT01726920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naratriptan
Description: Tablets containing naratriptan 2,5 mg
Study NCT01726920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: Tablets containing naproxen 500 mg
Study NCT01758393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT03634358 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar scissors
Study NCT03634358 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classic scalpel
Study NCT02546674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: A daily dose of 300 mg was given to all participants as two 150 mg capsules BID. The prescription of study drug was not study dependent and followed medical needs of the participant only. The study treatment was administered for 24 months.
Study NCT03314220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: preoperative preparation
Description: Participants in the experimental group received standard care plus our newly developed, multicomponent family-centered preoperative preparation program. This program included the following: (1) a tour of the preoperative area and recovery room; (2) a 4-min cartoon video entitled 'I am not afraid of surgery,' which was tailored to the child; this video included 29 scenes that depicted a boy's surgical journey with a particular emphasis on strategies for addressing postoperative pain; and (3) familiarization with medical equipment such as name badges, disposable hair caps, anesthetic masks, EKG leads, and pulse oximeters, which were placed on a doll, to help children understand the surgical instruments and promote better cooperation at the time of anesthesia induction.
Study NCT02555761 — intervention group
Intervention type: DRUG
Intervention: Alcaftadine Ophthalmic Solution 0.25%
Description: Alcaftadine Ophthalmic Solution 0.25% (Lastacaft®) as prescribed as standard of care in clinical practice.
Study NCT02467387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)
Description: One time infusion Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg.
Study NCT02467387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactated Ringer's Solution
Description: One time infusion 1.5mL/kg
Study NCT01636752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deprexis
Description: Online self-help with and without e-mail-support
Study NCT04612062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEE321
Description: CEE321 administered to all subjects
Study NCT04118686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CoRe software training plus non-invasive brain stimulation techniques (anodical tDCS / rTMS)
Description: CT program with Computerized cognitive training (CoRe) plus stimulation that modulates cortical activities by delivering strong magnetic pulses to the cortex through the scalp (rTMS) and weak electrical currents to the scalp to modulate neuronal transmembrane potential towards hyperpolarization or depolarization (tDCS).
Study NCT00744744 — intervention group
Intervention type: PROCEDURE
Intervention: quality-of-life assessment
Description: Survey
Study NCT00163189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: Liquid, daily, during 3 years and extended to 5 years Dosage: 0,46 mg/kg/week - the maximum dose should not exceed 50 µg/kg/day
Study NCT00992563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 10 mg/mL
Study NCT03008837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Military Field Stimulator
Description: The Military Field Stimulator (MFS/Neuro-Stim System), a percutaneous electrical neural field stimulation (PENFS) device evolved from PENS, is currently employed by the United States (US) military and used in the VA (contract number V797D-50453). There is some evidence based on a small trial of 20 postoperative patients that suggests PENS may have greater benefit than acupuncture for acute pain.
Study NCT01959685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Description: 125 mg Androxal, 250 mg Androxal separated by at least 7 days
Study NCT01959685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, single dose
Study NCT03132142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: 4x4 cm patch of 8% topical capsaicin applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
Study NCT03132142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans-cinnamaldehyde
Description: 1mL of 10% trans-cinnamaldehyde applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
Study NCT03132142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Menthol
Description: 1mL of 40% L-menthol applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
Study NCT03132142 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle patch
Description: Inert vehicle patch applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
Study NCT01936831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: INH was available in 100 mg tablets. INH was administered orally daily in the morning on an empty stomach. Doses of INH were given according to the weight bands and by cohort.
Study NCT01936831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: INH was available in 100 mg tablets. INH was administered orally daily in the morning on an empty stomach. Doses of INH were given according to the weight bands and by cohort.
Study NCT01936831 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Description: Vitamin B6 was administered at >= 25 mg daily and was obtained locally for use by study participants.
Study NCT01936831 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B6
Description: Vitamin B6 was administered at >= 25 mg daily and was obtained locally for use by study participants.
Study NCT03008837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Standard therapy for fibromyalgia will include physical therapy, medication management through the Anesthesiology Pain Clinic, and referral to a pain psychologist.
Study NCT00688402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: Single dose
Study NCT04118686 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: CoRe software training plus sham non-invasive brain stimulation (sham tDCS/ sham rTMS)
Description: CT program with Computerized cognitive training (CoRe) plus sham stimulation
Study NCT04504032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Participants self-administered rivaroxaban, 10 milligrams (mg) (1 tablet) orally once daily for 21 days.
Study NCT04504032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants self-administered rivaroxaban matching placebo orally once daily for 21 days.
Study NCT01858155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Study NCT01954303 — intervention group
Intervention type: OTHER
Intervention: Progress of CHD
Study NCT02039713 — intervention group
Intervention type: DEVICE
Intervention: DeSyne drug eluting stent group
Study NCT00233519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SomatoKine/IPLEX
Description: Cohort 1: self-administered subcuteanous injections of 0.5 mg/kg/day of iPlex for 8 weeks, followed by 1.0 mg/kg/day of iPlex for 16 weeks.~Cohort 2: consecutive 8 week treatments of 0.5, 1.0, and 2.0 mg/kg/day of iPlex for a total of 24 weeks by self-administered subcuteanous injection.
Study NCT00233519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SomatoKine/IPLEX
Description: Cohort 1: self-administered subcuteanous injections of 0.5 mg/kg/day of iPlex for 8 weeks, followed by 1.0 mg/kg/day of iPlex for 16 weeks.~Cohort 2: consecutive 8 week treatments of 0.5, 1.0, and 2.0 mg/kg/day of iPlex for a total of 24 weeks by self-administered subcuteanous injection.
Study NCT03445598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive and personalized CCBT
Description: Participants will go through an automated program. Participants will learn and practice the techniques of CBT through multimedia elements along with personalized content and interactive features in the program
Study NCT03445598 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feature-limited CCBT
Description: Participants will be going through an automated program. Participants will learn and practice the techniques of CBT in a plain-text format with reduced features.
Study NCT03445598 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist control
Description: Participants will be put on a waitlist for a period of 6 weeks.
Study NCT02763124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Verion-LenSx
Description: The Verion-LenSx femtosecond laser system will be used to create one or two partial-depth corneal arcuate incisions
Study NCT02364206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2228820
Study NCT01726140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Helmet CPAP
Description: the patient will receive CPAP treatment, at a PEEP level of 10 cmH2O and a FiO2 adjusted to maintain SpO2>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will repeat a spontaneous breathing trial with a Venturi mask at FiO2 = 50%, for 15 minutes and than a blood gas analysis will be repeated: if the PaO2/FiO2 will be \< 200 the patient will received a second treatment with CPAP; if PaO2/FiO2 will be >200, the patient will stop the treatment.
Study NCT01726140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Venturi Mask
Description: the patient will maintain spontaneous breathing, with a system for oxygen delivery at a FiO2 adjusted to maintain SpO2>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will do a trial for 15 minutes and after that a blood gas analysis will be repeated: if the PaO2/FiO2 will be \< 200 the patient will go on with the control treatment; if PaO2 /FiO2 will be >200, the patient will stop the treatment.
Study NCT02364206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT02364206 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Study NCT02520518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Study NCT02520518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03367494 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Measurement of Sweat Chloride and Sweat Bromide
Description: Sweat Chloride comparisons between ion exchange chromatography and fluorescence citrate-based sensors
Study NCT02520518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight maintenance